The MOF inhibitor MG149 evidenced anti-leukemic activities of MLL-fused leukemia and other AML cell models that are associated with HOXA9 over-expression, such as the CALM-AF10 fusion model U937, but also the K562 cell model (BCR-ABL fusion) that does not express HOXA9 [199], suggesting a more global epigenetic deregulation by MOF inhibitors that is not restricted to deregulated HOXA9 gene expression (Figure 2, point j; Table 2). The gene discussed is KMT2A; the disease is leukemia.